# Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma

> **NCT07097363** · PHASE2 · RECRUITING · sponsor: **University of Washington** · enrollment: 18 (estimated)

## Conditions studied

- B-Cell Non-Hodgkin Lymphoma
- Burkitt Lymphoma
- Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
- High Grade B-Cell Lymphoma, Not Otherwise Specified
- Primary Mediastinal Large B-Cell Lymphoma
- T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
- Transformed B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma to Diffuse Large B-Ce

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Aspiration
- **PROCEDURE:** Bone Marrow Biopsy
- **PROCEDURE:** Computed Tomography
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **PROCEDURE:** Echocardiography Test
- **BIOLOGICAL:** Epcoritamab
- **DRUG:** Etoposide
- **OTHER:** Fludeoxyglucose F-18
- **PROCEDURE:** Multigated Acquisition Scan
- **PROCEDURE:** Positron Emission Tomography
- **DRUG:** Prednisone
- **BIOLOGICAL:** Rituximab

## Key facts

- **NCT ID:** NCT07097363
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-07
- **Primary completion:** 2030-05-31
- **Final completion:** 2030-05-31
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07097363

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07097363, "Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07097363. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*